この記事を読む

初回治療としてのセルぺルカチニブ

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. Zhou C et al.N Engl J Med. 2023…

この記事を読む

FLAURA2: 抗がん剤+オシメルチニブまずPFS優越を証明

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. Planchard D et al.N Engl J Med. 2023 Nov 8.Epub…

この記事を読む

高齢者免疫療法の予後予測

Prognostic role of modified Glasgow Prognostic score in elderly non-small cell lung cancer patients treated with anti-PD…

この記事を読む

ロルラチニブとALKバリアント3

Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Typ…

この記事を読む

免疫療法後は何をしても変わらない?

Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens…

この記事を読む

オシメルチニブとアファチニブ交替療法、耐性機序が興味深い

Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single…

この記事を読む

肺炎のような粘液性肺腺癌の元は孤発型なのか?

Stepwise progression of invasive mucinous adenocarcinoma based on radiological and biological characteristics. Goto E et…

この記事を読む

T細胞エンゲ―ジャーは小細胞肺癌治療の新たな選択肢となるか?

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label…

この記事を読む

腫瘍治療電場療法、新たな希望か眉唾か

Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-sm…

この記事を読む

トラスツズマブ・デルクステカンは減量でもなお肺臓炎の発症率が高い

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Rand…